Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...

The approval was based on data from the phase 3 Marigold study that included patients aged 2 to 19 years with genetically confirmed CDKL5 gene mutation. Ztalmy ® (ganaxolone) is now available for the ...

CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterised by early-onset, treatment-resistant seizures, profound neurodevelopmental impairment and a ...

LONDON--(BUSINESS WIRE)--The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today ...

Rian McCann is almost seven years old. Her parents, Danielle and Frank described her as kind, sassy, smart and above all, resilient. Rian was born with CDKL5 Deficiency Disorder — which prevents her ...

The European Commission has granted marketing authorisation in the European Union (EU) for Ztalmy ® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with ...

“ZTALMY represents an important first for both Marinus and the CDD community and we are proud to make it available for patients by physician prescription,” said Christy Shafer, Chief Commercial ...

The mechanism behind a type of genetic epilepsy known as CDKL5 deficiency disorder has been elucidated, highlighting a potential target for novel therapeutic approaches. In a recent paper, researchers ...

Please provide your email address to receive an email when new articles are posted on . Marinus Pharmaceuticals Inc. announced the Unites States commercial launch of Ztalmy oral suspension for the ...

NDA filing acceptance enables opportunity to draw $30 million of additional cash under company’s credit financing agreement with Oaktree Capital Management, L.P. “The FDA’s acceptance of our NDA ...